• Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

    Source: Nasdaq GlobeNewswire / 02 Aug 2023 16:30:00   America/New_York

    ALPHARETTA, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will participate in the following investor conferences in August 2023:

    Chardan Virtual Ophthalmology Summit
    Age-Related Macular Degeneration and Diabetes-Related Eye Diseases Series
    Fireside Chat (Available on Demand)

    BTIG Virtual Biotechnology Conference
    Corporate Presentation and One-on-One Investor Meetings
    August 7, 2023 at 2:30 pm (Presentation)

    H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
    Panel Discussion, Corporate Presentation and One-on-One Investor Meetings
    August 16, 2023 at 11:00 am ET (Panel)

    A link to available live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations.

    About Clearside Biomedical, Inc.

    Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com.

    Source: Clearside Biomedical, Inc.


    Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

    Primary Logo

Share on,